Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Odyssey Therapeutics, Inc.

NASDAQ: ODTX · Life Sciences · 3 alerts · CIK 1882782

Share price
$19.36Close, Nov 16
Market cap
$931M
Shares outstanding
48.07MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Odyssey Therapeutics, Inc. filings on SEC EDGAR ↗

7:01 AM ET 8-K
Clinical Trial Data

Odyssey Therapeutics Clinical Trial Data

Odyssey Therapeutics announced positive Phase 2a results for its oral RIPK2 inhibitor, OD-001, in patients with moderate-to-severe ulcerative colitis. The trial met its primary endpoint with a 27% clinical remission rate at the 20 mg BID dose at Week 12, showing significant correlation between clinical efficacy and inflammatory biomarkers.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.